BOSTON--(BUSINESS WIRE)--Monte Rosa Therapeutics, a biotechnology company focused on developing precision medicines to degrade disease-causing proteins, today announced it is scheduled to present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 13, 2021, at 11:00 a.m. ET. Markus Warmuth, M.D., CEO of Monte Rosa, will be presenting a corporate overview followed by a Q&A session.
About Monte Rosa
Monte Rosa Therapeutics is a biotechnology company developing molecular glues to degrade disease-causing proteins. The company has created a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland. For more information, visit www.monterosatx.com.